Mitochondrial Contact Site Stabilization

Target: VDAC1 Composite Score: 0.455 Price: $0.52▲5.7% Citation Quality: Pending neurodegeneration Status: active
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
📄 Export → LaTeX
Select venue
arXiv Preprint NeurIPS Nature Methods PLOS ONE
🌐 Open in Overleaf →
📖 Export BibTeX
⚠ Low Validation Senate Quality Gates →
Evidence Strength Pending (0%)
5
Citations
1
Debates
5
Supporting
3
Opposing
Quality Report Card click to collapse
C
Composite: 0.455
Top 73% of 1875 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
C+ Mech. Plausibility 15% 0.50 Top 76%
C+ Evidence Strength 15% 0.50 Top 57%
C+ Novelty 12% 0.50 Top 82%
C+ Feasibility 12% 0.50 Top 65%
F Impact 12% 0.00 Top 50%
C+ Druggability 10% 0.50 Top 57%
C+ Safety Profile 8% 0.50 Top 57%
C+ Competition 6% 0.50 Top 77%
C+ Data Availability 5% 0.50 Top 71%
C+ Reproducibility 5% 0.50 Top 63%
Evidence
5 supporting | 3 opposing
Citation quality: 0%
Debates
1 session A+
Avg quality: 0.92
Convergence
0.00 F 30 related hypothesis share this target

From Analysis:

Which specific metabolic pathways in APOE4+ microglia are most therapeutically tractable?

While APOE4 disrupts microglial metabolism broadly, the debate didn't identify which specific disrupted pathways offer the best therapeutic targets. This prioritization is needed for focused drug development efforts. Source: Debate session sess_SDA-2026-04-04-gap-neuroinflammation-microglial-20260404 (Analysis: SDA-2026-04-04-gap-neuroinflammation-microglial-20260404)

→ View full analysis & debate transcript

Description

Target VDAC1-GRP75-IP3R1 complex to restore mitochondrial-ER communication and metabolic flexibility by addressing fundamental cellular architecture defects

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["APOE4 Microglial Cellular Architecture Defects
MAM Mitochondria-ER Contact Sites"] B["VDAC1 Outer Membrane Channel
Mitochondrial Calcium Entry"] C["GRP75 Chaperone Bridge
VDAC1-IP3R1 Tether"] D["IP3R1 ER Calcium Channel
Endoplasmic Reticulum Release"] E["MAM Complex Destabilized
VDAC1-GRP75-IP3R1 Disrupted"] F["Mitochondrial Calcium Signaling Impaired
ATP Synthesis Uncoupled"] G["Metabolic Flexibility Lost
Energy Crisis Worsens"] H["VDAC1-IP3R1 Stabilizer Treatment
Pharmacological MAM Restoration"] I["Mitochondria-ER Communication Restored
Microglial Metabolic Rescue"] A --> E B --> C C --> D E -.->|"disrupts"| B E --> F F --> G H --> C H --> I style E fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8 style I fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.50 (15%) Evidence 0.50 (15%) Novelty 0.50 (12%) Feasibility 0.50 (12%) Impact 0.00 (12%) Druggability 0.50 (10%) Safety 0.50 (8%) Competition 0.50 (6%) Data Avail. 0.50 (5%) Reproducible 0.50 (5%) KG Connect 0.50 (8%) 0.455 composite
8 citations 8 with PMID 8 medium Validation: 0% 5 supporting / 3 opposing
For (5)
5
3
(3) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
8
MECH 8CLIN 0GENE 0EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
FMO2 Prevents Pathological Cardiac Hypertrophy by …SupportingMECHCirculation MEDIUM2025-PMID:40489543-
VSTM2L protects prostate cancer cells against ferr…SupportingMECHNat Commun MEDIUM2025-PMID:39880844-
Augmented microglial endoplasmic reticulum-mitocho…SupportingMECHNat Commun MEDIUM2024-PMID:38890305-
Mitochondrial Tumor Suppressor 1A Attenuates Myoca…SupportingMECHCirculation MEDIUM2025-PMID:40583767-
Zhizichi decoction alleviates depressive-like beha…SupportingMECHJ Ethnopharmaco… MEDIUM2025-PMID:40074101-
VDAC1, mitochondrial dysfunction, and Alzheimer&#x…OpposingMECHPharmacol Res MEDIUM2018-PMID:29551631-
Mitochondria-associated membranes (MAMs): molecula…OpposingMECHFEBS Open Bio MEDIUM2026-PMID:41071679-
VDAC1: A Key Player in the Mitochondrial Landscape…OpposingMECHBiomolecules MEDIUM2024-PMID:39858428-
Legacy Card View — expandable citation cards

Supporting Evidence 5

FMO2 Prevents Pathological Cardiac Hypertrophy by Maintaining the ER-Mitochondria Association Through Interact… MEDIUM
FMO2 Prevents Pathological Cardiac Hypertrophy by Maintaining the ER-Mitochondria Association Through Interaction With IP3R2-Grp75-VDAC1.
Circulation · 2025 · PMID:40489543
VSTM2L protects prostate cancer cells against ferroptosis via inhibiting VDAC1 oligomerization and maintaining… MEDIUM
VSTM2L protects prostate cancer cells against ferroptosis via inhibiting VDAC1 oligomerization and maintaining mitochondria homeostasis.
Nat Commun · 2025 · PMID:39880844
Augmented microglial endoplasmic reticulum-mitochondria contacts mediate depression-like behavior in mice indu… MEDIUM
Augmented microglial endoplasmic reticulum-mitochondria contacts mediate depression-like behavior in mice induced by chronic social defeat stress.
Nat Commun · 2024 · PMID:38890305
Mitochondrial Tumor Suppressor 1A Attenuates Myocardial Infarction Injury by Maintaining the Coupling Between … MEDIUM
Mitochondrial Tumor Suppressor 1A Attenuates Myocardial Infarction Injury by Maintaining the Coupling Between Mitochondria and Endoplasmic Reticulum.
Circulation · 2025 · PMID:40583767
Zhizichi decoction alleviates depressive-like behaviors through modulating mitochondria-associated membrane vi… MEDIUM
Zhizichi decoction alleviates depressive-like behaviors through modulating mitochondria-associated membrane via the IP3R3-GRP75-VDAC1 complex.
J Ethnopharmacol · 2025 · PMID:40074101

Opposing Evidence 3

VDAC1, mitochondrial dysfunction, and Alzheimer's disease. MEDIUM
Pharmacol Res · 2018 · PMID:29551631
Mitochondria-associated membranes (MAMs): molecular organization, cellular functions, and their role in health… MEDIUM
Mitochondria-associated membranes (MAMs): molecular organization, cellular functions, and their role in health and disease.
FEBS Open Bio · 2026 · PMID:41071679
VDAC1: A Key Player in the Mitochondrial Landscape of Neurodegeneration. MEDIUM
Biomolecules · 2024 · PMID:39858428
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-09 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Based on the knowledge gap and the enrichment data showing key microglial functions, here are my novel therapeutic hypotheses:

1. Metabolic Checkpoint Reprogramming via TREM2-mTOR Axis

APOE4 microglia exhibit disrupted mTOR signaling that locks them in a glycolytic state, preventing the metabolic flexibility needed for effective amyloid clearance. Targeting the TREM2-mTOR metabolic checkpoint could restore oxidative metabolism and enhance phagocytic capacity. Small molecule mTOR modulators specifically designed for CNS penetration could selectively reactivate oxidative phosphorylation

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

I'll critically evaluate each hypothesis, focusing on weaknesses in the evidence and logic, alternative explanations, and missing key considerations.

1. Metabolic Checkpoint Reprogramming via TREM2-mTOR Axis

Specific Weaknesses:

  • Oversimplified causality: The hypothesis assumes APOE4 "locks" microglia in glycolysis, but metabolic states are highly dynamic and context-dependent
  • Missing cell-type specificity: TREM2 is expressed on multiple myeloid cells, not just microglia - CNS targeting claims are unsupported
  • Circular reasoning: Uses TREM2 enrichment as evidence f

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

UPDATED FEASIBILITY WITH CLINICAL DATA

TIER 1 TARGETS - IMMEDIATE COMMERCIAL VIABILITY

1. NAD+ Salvage Pathway (NAMPT/CD38) - HIGHEST PRIORITY

Clinical Validation:

  • NCT04430517: McLean Hospital studying NR in MCI/mild AD (n=50, active)
  • NCT05617508: Completed Phase 2 dose optimization (n=80, up to 3g daily)
  • NCT05040321: Brigham & Women's testing MIB-626 BBB penetration
  • NCT07278492: MIB-626 in Down syndrome (Alzheimer's model)
Competitive Landscape:
  • ChromaDex Corp: NIAGEN® (NR supplement) - $100M+ revenue
  • Elysium Health: BASI

Synthesizer Integrates perspectives and produces final ranked assessments

Based on the Theorist's hypotheses, Skeptic's critiques, and Expert's feasibility assessment, here is my synthesis with scored rankings:

Price History

0.460.490.52 0.54 0.43 2026-04-212026-04-252026-04-28 Market PriceScoreevidencedebate 8 events
7d Trend
Stable
7d Momentum
▲ 7.1%
Volatility
High
0.0527
Events (7d)
7

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (8)

No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score
0.50
32.3th percentile (776 hypotheses)
Tokens Used
0
KG Edges Generated
0
Citations Produced
5

Cost Ratios

Cost per KG Edge
0.00 tokens
Lower is better (baseline: 2000)
Cost per Citation
0.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
0.00 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.050
10% weight of efficiency score
Adjusted Composite
0.505

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for VDAC1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for VDAC1 →
Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

KG Entities (21)

APOE4CD38DGAT1MTORMTOR signalingNAD+ biosynthesisNAD+ levelsNAMPTSLC16A1SMPD1TREM2VDAC1amyloid clearancelactate transportlipid droplet formationmTOR modulatorsmetabolic flexibilitymitochondrial-ER contactsoxidative phosphorylationsirtuin function

Related Hypotheses

Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration
Score: 0.907 | neurodegeneration
Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse
Score: 0.895 | neurodegeneration
SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence
Score: 0.893 | neurodegeneration
TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration
Score: 0.892 | neurodegeneration
Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial State Transition Restoration
Score: 0.887 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (13 edges)

activates (2)

NAD+ biosynthesissirtuin functionAPOE4MTOR signaling

catalyzes (1)

DGAT1lipid droplet formation

causes (1)

APOE4lipid droplet formation

disrupts (1)

APOE4mitochondrial-ER contacts

enhances (1)

mTOR modulatorsoxidative phosphorylation

inhibits (2)

APOE4NAMPTCD38NAD+ levels

mediates (2)

TREM2amyloid clearanceSLC16A1lactate transport

regulates (3)

MTORmetabolic flexibilityVDAC1mitochondrial-ER contactsSMPD1sphingolipid metabolism

Mechanism Pathway for VDAC1

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    NAD__biosynthesis["NAD+ biosynthesis"] -->|activates| sirtuin_function["sirtuin function"]
    TREM2["TREM2"] -->|mediates| amyloid_clearance["amyloid clearance"]
    APOE4["APOE4"] -.->|inhibits| NAMPT["NAMPT"]
    APOE4_1["APOE4"] -->|activates| MTOR_signaling["MTOR signaling"]
    MTOR["MTOR"] -->|regulates| metabolic_flexibility["metabolic flexibility"]
    APOE4_2["APOE4"] -->|causes| lipid_droplet_formation["lipid droplet formation"]
    DGAT1["DGAT1"] -->|catalyzes| lipid_droplet_formation_3["lipid droplet formation"]
    APOE4_4["APOE4"] -->|disrupts| mitochondrial_ER_contacts["mitochondrial-ER contacts"]
    VDAC1["VDAC1"] -->|regulates| mitochondrial_ER_contacts_5["mitochondrial-ER contacts"]
    SLC16A1["SLC16A1"] -->|mediates| lactate_transport["lactate transport"]
    SMPD1["SMPD1"] -->|regulates| sphingolipid_metabolism["sphingolipid metabolism"]
    mTOR_modulators["mTOR modulators"] -->|enhances| oxidative_phosphorylation["oxidative phosphorylation"]
    style NAD__biosynthesis fill:#81c784,stroke:#333,color:#000
    style sirtuin_function fill:#4fc3f7,stroke:#333,color:#000
    style TREM2 fill:#4fc3f7,stroke:#333,color:#000
    style amyloid_clearance fill:#4fc3f7,stroke:#333,color:#000
    style APOE4 fill:#ce93d8,stroke:#333,color:#000
    style NAMPT fill:#ce93d8,stroke:#333,color:#000
    style APOE4_1 fill:#ce93d8,stroke:#333,color:#000
    style MTOR_signaling fill:#81c784,stroke:#333,color:#000
    style MTOR fill:#4fc3f7,stroke:#333,color:#000
    style metabolic_flexibility fill:#4fc3f7,stroke:#333,color:#000
    style APOE4_2 fill:#ce93d8,stroke:#333,color:#000
    style lipid_droplet_formation fill:#4fc3f7,stroke:#333,color:#000
    style DGAT1 fill:#4fc3f7,stroke:#333,color:#000
    style lipid_droplet_formation_3 fill:#4fc3f7,stroke:#333,color:#000
    style APOE4_4 fill:#ce93d8,stroke:#333,color:#000
    style mitochondrial_ER_contacts fill:#4fc3f7,stroke:#333,color:#000
    style VDAC1 fill:#4fc3f7,stroke:#333,color:#000
    style mitochondrial_ER_contacts_5 fill:#4fc3f7,stroke:#333,color:#000
    style SLC16A1 fill:#4fc3f7,stroke:#333,color:#000
    style lactate_transport fill:#4fc3f7,stroke:#333,color:#000
    style SMPD1 fill:#4fc3f7,stroke:#333,color:#000
    style sphingolipid_metabolism fill:#81c784,stroke:#333,color:#000
    style mTOR_modulators fill:#4fc3f7,stroke:#333,color:#000
    style oxidative_phosphorylation fill:#4fc3f7,stroke:#333,color:#000

3D Protein Structure

🧬 VDAC1 — Search for structure Click to search RCSB PDB
🔍 Searching RCSB PDB for VDAC1 structures...
Querying Protein Data Bank API

Source Analysis

Which specific metabolic pathways in APOE4+ microglia are most therapeutically tractable?

neurodegeneration | 2026-04-08 | completed

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (5)

Lipid Droplet Dynamics as Therapeutic Lever
Score: 0.46 · DGAT1
Purinergic-Metabolic Coupling Restoration
Score: 0.46 · P2RY12
Lactate Shuttle Pathway Enhancement
Score: 0.46 · SLC16A1
Sphingolipid Metabolism Rebalancing
Score: 0.46 · SMPD1
NAD+ Salvage Pathway Optimization
Score: 0.46 · NAMPT
→ View all analysis hypotheses
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.